Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease
New England Journal of Medicine2007Vol. 356(8), pp. 775–789
Citations Over TimeTop 1% of 2007 papers
Peter Calverley, Julie A. Anderson, Bartolomé R. Celli, Gary T. Ferguson, Christine Jenkins, Paul Jones, Julie Yates, Jørgen Vestbo
Abstract
The reduction in death from all causes among patients with COPD in the combination-therapy group did not reach the predetermined level of statistical significance. There were significant benefits in all other outcomes among these patients. (ClinicalTrials.gov number, NCT00268216 [ClinicalTrials.gov].).
Related Papers
- → Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD(2004)74 cited
- → THE TOWARDS A REVOLUTION IN COPD HEALTH (TORCH) STUDY: FLUTICASONE PROPIONATE/SALMETEROL IMPROVES SURVIVAL IN COPD OVER THREE YEARS(2006)16 cited
- → The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD(2010)16 cited
- → Wixela Inhub: A Generic Equivalent Treatment Option for Patients with Asthma or COPD(2020)3 cited
- → Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD*1(2004)3 cited